Hypothermia in a Patient with Carcinoid Syndrome during Treatment with Parachlorophenylalanine

Publisher Website
Google Scholar
Abstract
PARA-CHLOROPHENYLALANINE (Fenclonine, PCP) is a drug that reduces levels of serotonin (5-hydroxytryptamine) in the tissues of animals and of man by inhibition of the rate-limiting enzyme in its biosynthesis, tryptophan hydroxylase. Recently, it has been used experimentally in the therapy of patients with carcinoid syndrome.1 , 2 The clinical manifestation of carcinoid syndrome most likely to be relieved by PCP therapy is the one that is thought to be mediated by serotonin — that is, diarrhea. Other humoral manifestations of carcinoid syndrome have been either shown or assumed to be mediated by other factors.3 The biochemical effect of PCP administration in man . . .